Lazard Asset Management LLC raised its position in shares of Renalytix Plc (NASDAQ:RNLX – Get Rating) by 5.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 264,998 shares of the company’s stock after purchasing an additional 13,837 shares during the period. Lazard Asset Management LLC owned 0.71% of Renalytix worth $339,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Pinnacle Associates Ltd. lifted its position in shares of Renalytix by 33.2% during the third quarter. Pinnacle Associates Ltd. now owns 453,126 shares of the company’s stock worth $580,000 after acquiring an additional 112,890 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Renalytix by 97.8% during the second quarter. JPMorgan Chase & Co. now owns 88,410 shares of the company’s stock worth $218,000 after acquiring an additional 43,724 shares in the last quarter. Pentwater Capital Management LP lifted its position in shares of Renalytix by 11.1% during the second quarter. Pentwater Capital Management LP now owns 250,000 shares of the company’s stock worth $613,000 after acquiring an additional 25,000 shares in the last quarter. Private Advisor Group LLC purchased a new stake in shares of Renalytix during the first quarter worth $92,000. Finally, State Street Corp lifted its position in shares of Renalytix by 58.0% during the first quarter. State Street Corp now owns 21,093 shares of the company’s stock worth $146,000 after acquiring an additional 7,747 shares in the last quarter. 11.81% of the stock is owned by institutional investors.
Renalytix Trading Down 3.6 %
Shares of RNLX stock opened at $3.26 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.58 and a current ratio of 2.58. Renalytix Plc has a 52-week low of $1.05 and a 52-week high of $8.78. The company has a market capitalization of $152.59 million, a PE ratio of -4.13 and a beta of 2.59. The business’s fifty day moving average is $2.84 and its 200 day moving average is $2.07.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright dropped their target price on Renalytix from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, December 2nd.
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score.
- Get a free copy of the StockNews.com research report on Renalytix (RNLX)
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
- Taiwan Semiconductor Manufacturing Expanding in the West
Want to see what other hedge funds are holding RNLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Renalytix Plc (NASDAQ:RNLX – Get Rating).
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.